Carcinogenesis, Vol. 22, No. 6, 839-849,
June 2001
© 2001 Oxford University Press
COMMENTARY |
Understanding the genotoxicity of tamoxifen?
Institute of Cancer Research, Haddow Laboratories, Cotswold Road, Sutton SM2 5NG, UK Email: davidp{at}icr.ac.uk
Tamoxifen is an anti-oestrogenic drug widely used for adjuvant therapy of breast cancer. Its use has caused an increased incidence of endometrial cancer and it is also a potent carcinogen in rat liver. Since the demonstration that tamoxifen forms covalent DNA adducts in rat liver, many investigations of its mechanism of carcinogenic action have focused on the examination of human and animal tissues for the presence of tamoxifen–DNA adducts, the identification of their structures and the determination of the metabolic pathways that lead to their formation. This article reviews the current evidence for genotoxic mechanisms for tamoxifen carcinogenicity, and discusses some inconsistencies in the data.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. J. Ho, C. E. Bass, A. H. K. Kroemer, C. Ma, E. Terwilliger, and S. J. Karp Optimized adeno-associated virus 8 produces hepatocyte-specific Cre-mediated recombination without toxicity or affecting liver regeneration Am J Physiol Gastrointest Liver Physiol, August 1, 2008; 295(2): G412 - G419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Chu, A. Fyles, E. M. Sellers, D. R. McCready, J. Murphy, T. Pal, and S. A. Narod Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use Carcinogenesis, October 1, 2007; 28(10): 2139 - 2142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Wu, M. C. Pike, L. D. Williams, D. Spicer, C.-C. Tseng, M. I. Churchwell, and D. R. Doerge Tamoxifen, Soy, and Lifestyle Factors in Asian American Women With Breast Cancer J. Clin. Oncol., July 20, 2007; 25(21): 3024 - 3030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Arlt, E. Frei, and H. H. Schmeiser ECNIS-sponsored workshop on biomarkers of exposure and cancer risk: DNA damage and DNA adduct detection and 6th GUM-32P-postlabelling workshop, German Cancer Research Center, Heidelberg, Germany, 29-30 September 2006 Mutagenesis, January 1, 2007; 22(1): 83 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. P. Tryndyak, L. Muskhelishvili, O. Kovalchuk, R. Rodriguez-Juarez, B. Montgomery, M. I. Churchwell, S. A. Ross, F. A. Beland, and I. P. Pogribny Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis Carcinogenesis, August 1, 2006; 27(8): 1713 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Jin, K. Y. Arai, G. Watanabe, A. K. Suzuki, S. Takahashi, and K. Taya The Stimulatory Role of Estrogen on Sperm Motility in the Male Golden Hamster (Mesocricetus auratus) J Androl, July 1, 2005; 26(4): 478 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Phillips, A. Hewer, M. R. Osborne, K. J. Cole, C. Churchill, and V. M. Arlt Organ specificity of DNA adduct formation by tamoxifen and {alpha}-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment Mutagenesis, July 1, 2005; 20(4): 297 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Schild, D. H. Phillips, M. R. Osborne, A. Hewer, F. A. Beland, M. I. Churchwell, K. Brown, M. Gaskell, E. Wright, and M. C. Poirier Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods Mutagenesis, March 1, 2005; 20(2): 115 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Beland, M. I. Churchwell, D. R. Doerge, D. R. Parkin, D. Malejka-Giganti, A. Hewer, D. H. Phillips, P. L. Carmichael, G. Gamboa da Costa, and M. M. Marques Electrospray Ionization-Tandem Mass Spectrometry and 32P-Postlabeling Analyses of Tamoxifen-DNA Adducts in Humans J Natl Cancer Inst, July 21, 2004; 96(14): 1099 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Schild, R. L. Divi, F. A. Beland, M. I. Churchwell, D. R. Doerge, G. Gamboa da Costa, M. M. Marques, and M. C. Poirier Formation of Tamoxifen-DNA Adducts in Multiple Organs of Adult Female Cynomolgus Monkeys Dosed with Tamoxifen for 30 Days Cancer Res., September 15, 2003; 63(18): 5999 - 6003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Poirier and L. J. Schild The Genotoxicity of Tamoxifen: Extent and Consequences, Kona, Hawaii, January 23, 2003 Mutagenesis, July 1, 2003; 18(4): 395 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. V. Jensen and V. C. Jordan The Estrogen Receptor: A Model for Molecular Medicine Clin. Cancer Res., June 1, 2003; 9(6): 1980 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan and M. Morrow Re: Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999 J Natl Cancer Inst, May 7, 2003; 95(9): 683 - 684. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Rochat, E. M. J. Gillam, and M. S. Lennard Evaluation of Recombinant Cytochromes P450 Activity in Metabolic Pathways Drug Metab. Dispos., January 1, 2003; 31(1): 145 - 146. [Full Text] [PDF]
|
|
|
|
|
|
M. Yadollahi-Farsani, D. S. Davies, and A. R. Boobis The mutational signature of {alpha}-hydroxytamoxifen at Hprt locus in Chinese hamster cells Carcinogenesis, November 1, 2002; 23(11): 1947 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chen, G. Gamboa da Costa, M.M. Marques, S. D. Shelton, F. A. Beland, and M. G. Manjanatha Mutations induced by {alpha}-hydroxytamoxifen in the lacI and cII genes of Big Blue transgenic rats Carcinogenesis, October 1, 2002; 23(10): 1751 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Dardes, D. Bentrem, R. M. O'Regan, J. M. Schafer, and V. C. Jordan Effects of the New Selective Estrogen Receptor Modulator LY353381.HCl (Arzoxifene) on Human Endometrial Cancer Growth in Athymic Mice Clin. Cancer Res., December 1, 2001; 7(12): 4149 - 4155. [Abstract] [Full Text] [PDF]
|
|